Mesoblast develops cell therapies for inflammatory diseases, led by Ryoncil, approved in the US for a transplant complication in children. MESO last reported earnings on Thu, Feb 26, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 27 | Piper Sandler | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in MESO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MESO is in one of them and how their past MESO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MESO in an article yet. Here's the latest on the wider market.
About Mesoblast
Mesoblast is a biotechnology company based in Melbourne, Australia, that develops cell therapies made from mesenchymal cells taken from healthy adult bone marrow. Its lead product, Ryoncil, is approved in the United States to treat a severe complication of bone marrow transplants in children and is sold to physicians at transplant centers. The company is also developing these cells for other inflammatory conditions, including chronic low back pain and heart failure. The cells can be given without donor matching and are produced at industrial scale.
- Headquarters
- Melbourne, Victoria, Australia